Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection
This article was originally published in The Pink Sheet Daily
Risk management program couldn't save psoriasis drug. Decision is final, firm says.
You may also be interested in...
Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006
The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.
President Obama praises Hamburg's "reputation of integrity" and record of public health acheivements in making nominations March 14.